Tropical Spastic Paraparesis Clinical Trial
Official title:
Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1
Urological physical therapy is described to improve urinary symptoms in patients with myelopathy or neurological dysfunction and to increase the quality of life. Although it was never tested on HTLV-1 associated overactive bladder syndrome, an disabling disease that is common seen in HAM/TSP patients but can also appear as an isolated form. Our hypothesis is that urological physical therapy can improve urinary symptoms like incontinence, urgency and nocturia in HTLV-1 infected population with those complains.
The T-lymphotropic virus type 1 (HTLV-1) is an human retrovirus that was proved to be the
main agent of the acute T cell lymphoma/leukemia (ATLL) and a progressive neurological
disease called HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP).
The HTLV-1 was first isolated in 1980 and it is endemic in Japan, Caribbean, Africa and South
America. It is estimated that about 20 million people is infected worldwide. In Brazil it is
present in all states with variable prevalences. The factors associated with HTLV-1
transmission in Brazil are related to the social and demographic condition, characterized by
rural exodus and increase of urban population in the coast areas.
Several studies based in Brazil reported that the epicenter of HTLV-1 infection is on Bahia,
Maranhão and Pernambuco with the highest prevalence of 1,8% in Salvador, Bahia capital.
The urinary incontinence is a bladder-sphincter disturbance often found in HTLV-1 patients.
In this infection the most common pathology finding is overactive bladder syndrome due
detrusor overactivity and sphincter-detrusor dyssynergia and the symptoms are urgency,
nocturia and incontinence.
This disabling disease is associated with psychosocial issues like loss of self confidence,
social isolation and reduced quality of life.
The physical therapy treatment have the objective of promote social adequacy and reestablish
the bladder function. It is based on resources like: bladder reeducation, biofeedback,
kinesiotherapy of the pelvic wall, utilization of vaginal cones and electrostimulation.
Those can be associated or not with anticholinergic drugs and bladder catheterization.
The need of urologic and gynecologic physical therapy follow up in patients with HTLV-1 and
neurogenic bladder is important to reduce disability, preserve pelvic muscles and renal
function.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01472263 -
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
|
Phase 3 | |
Completed |
NCT00001785 -
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
|
Phase 2 | |
Completed |
NCT02655471 -
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
|
Early Phase 1 | |
Completed |
NCT00001156 -
Assessment of Patients With Multiple Sclerosis (MS)
|
N/A | |
Recruiting |
NCT00001778 -
Evaluation of Patients With HAM/TSP
|
||
Completed |
NCT00034723 -
MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
|
N/A |